Key Highlights
● A prospective study of Renuvion in patients undergoing facelift surgery was published in Plastic and Reconstructive Surgery Global Open.
● Elastin fiber density rose 30 percent and elastin staining intensity rose 55 percent versus untreated control tissue at Day 180.
● The single-arm study enrolled seven patients at two United States sites, and six completed the Day 180 evaluation.
● Inflammation was 34 percent lower than untreated tissue, and the release says no significant fibrosis or abnormal vascularization was observed.
Apyx Medical Corporation (NASDAQ:APYX) reported in a Form 8-K that a new clinical study of its Renuvion technology has been published in Plastic and Reconstructive Surgery Global Open. The company says the prospective study, conducted in patients undergoing facelift surgery, found that Renuvion treatment increased elastin fiber density by 30 percent and elastin staining intensity by 55 percent compared with untreated control tissue at Day 180. The report was filed under Item 8.01, Other Events, with a press release attached as Exhibit 99.1.
How the Study Was Designed
According to the press release, the study was a prospective, single-arm, post-market study conducted at two investigational sites in the United States. It evaluated seven patients undergoing lower rhytidectomy, the surgical term for a lower facelift. Renuvion was applied to subdermal tissue, and untreated areas of the same patients served as internal controls. Six of the seven participants completed the Day 180 evaluation. The paper is cited as Kimbrell, M. L., and Holcomb, J. D. (2026), published in Plastic and Reconstructive Surgery Global Open, Volume 14, issue 9, article e8116.
What the Company Reports
The press release lists the following results at Day 180 among the six participants who completed the evaluation. Elastin fiber density increased by 30 percent and elastin staining intensity by 55 percent. Inflammation was 34 percent lower than in untreated control tissue, and the incidence of elastin expression, described as a regenerative response, was 27 percent higher. The release says no significant fibrosis, abnormal vascularization or epithelial disruption was observed.
On clinical assessments, the release says all participants demonstrated physician-assessed and patient-assessed aesthetic improvement. It also reports that all patients said they experienced improvement, were satisfied and would recommend the procedure, and that all reported improvements in skin elasticity, radiance and youthfulness. Because the study enrolled only seven patients, and only six completed Day 180, each patient accounts for a large share of every percentage in the release. The design is single-arm, with untreated areas of the same patients serving as the controls, rather than a separate group of patients receiving a different treatment.
Charlie Goodwin, Apyx Medical's President and Chief Executive Officer, is quoted in the release as saying that the findings "provide important new evidence supporting the biological basis for the clinical benefits observed with Renuvion."
The release describes Renuvion as helium plasma radiofrequency technology that provides controlled heat delivery to tissue, marketed for cosmetic surgery, and says the J-Plasma variant is used in hospital surgical settings. It says Renuvion is supported by more than 90 clinical documents and describes the AYON Body Contouring System as an FDA-cleared integrated platform that combines fat removal, contouring, electrosurgery and Renuvion capabilities. Apyx Medical describes itself as a developer of helium plasma platform technology products, including Renuvion and AYON for cosmetic surgery and J-Plasma for hospital surgical applications. Its shares trade on Nasdaq under the symbol APYX.
What the Filing Does Not Say
The 8-K does not report any financial results, sales figures or guidance, and it does not say the study result changes the regulatory status or labeling of any product. The study is described as a post-market study of a technology the company already sells, and the 8-K text does not mention any new indication being sought or granted. It also does not say whether the company plans further studies on the same endpoints, or whether larger trials are being considered to confirm the findings in a bigger group of patients.
Renuvion Elastin Study Published in Volume 14
The publication itself, cited in the release by its volume and article number, is the primary source for the study methods, tissue measurements and any limitations the authors discuss.



_11_17_2026_20_37_58_946960.jpg)


Please wait processing your request...